Decoy Therapeutics Inc., formerly Salarius Pharmaceuticals, Inc., is a preclinical-stage biotechnology company that is leveraging machine learning and artificial intelligence (AI) tools alongside high-speed synthesis techniques to design, engineer and manufacture peptide conjugate drug candidates that target serious unmet medical needs. The Company’s initial pipeline is focused on respiratory viruses and GI cancers. In parallel, the Company is advancing discovery programs, including multi-virus decoy candidates designed to address overlapping respiratory threats, and cell-based and organoid-level validation of novel G protein-coupled receptor (GPCR)-targeted drug candidates outside of antivirals.

Events Timeline

No data

News

8.5

02-05PRnewswire

Decoy Therapeutics to Participate in Corporate Connect Webinar

8.5

02-04PRnewswire

Decoy Therapeutics Partners with Gates Foundation on Global Access Commitment

7.5

02-04Newsfilter

Decoy Therapeutics Announces Global Access Commitment with Gates Foundation

6.0

01-23Benzinga

Roth Capital Initiates Buy Rating on vTv Therapeutics with $58 Price Target

8.5

01-13PRnewswire

Decoy Therapeutics Secures Gates Foundation Funding to Advance Global Manufacturing of Antivirals

Valuation Metrics

The current forward P/E ratio for Decoy Therapeutics Inc (DCOY.O) is --, compared to its 5-year average forward P/E of --. For a more detailed relative valuation and DCF analysis to assess Decoy Therapeutics Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

5Y Average PE

Current PE

NaN

Overvalued PE

Undervalued PE

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

5Y Average EV/EBITDA

Current EV/EBITDA

NaN

Overvalued EV/EBITDA

Undervalued EV/EBITDA

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

Current PS

NaN

Overvalued PS

Undervalued PS

Financials

AI Analysis

Annual

Quarterly

Whales Holding DCOY

Trading Trends

People Also Watch

Frequently Asked Questions

What is Decoy Therapeutics Inc (DCOY) stock price today?

The current price of DCOY is 0.661 USD — it has decreased -2.94

What is Decoy Therapeutics Inc (DCOY)'s business?

What is the price predicton of DCOY Stock?

Wall Street analysts forecast DCOY stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for DCOY is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Decoy Therapeutics Inc (DCOY)'s revenue for the last quarter?

Decoy Therapeutics Inc revenue for the last quarter amounts to 0.00 USD, decreased

What is Decoy Therapeutics Inc (DCOY)'s earnings per share (EPS) for the last quarter?

Decoy Therapeutics Inc. EPS for the last quarter amounts to -1.81 USD, decreased -84.09

How many employees does Decoy Therapeutics Inc (DCOY). have?

Decoy Therapeutics Inc (DCOY) has 2 emplpoyees as of March 03 2026.

What is Decoy Therapeutics Inc (DCOY) market cap?

Today DCOY has the market capitalization of 7.40M USD.

DCOY Overview